Bavarian Nordic Secures Major Contract for Smallpox Vaccine Production

BARDA Invests $1.568 Billion in Replenishing National Stockpile

Boosting Public Preparedness for Potential Outbreaks

Bavarian Nordic A/S, a leading biotechnology company focused on developing and manufacturing smallpox vaccines, has announced a significant contract award from the US Biomedical Advanced Research and Development Authority (BARDA). The contract, valued at $1.568 billion, will enable Bavarian Nordic to partly replenish the US national stockpile of bulk vaccine required for future manufacturing and supply of freeze-dried vaccines.

The contract aligns with BARDA's mission to support the development and procurement of vaccines and other medical countermeasures against public health threats. The investment in replenishing the smallpox vaccine stockpile demonstrates the US government's commitment to enhancing its preparedness for potential outbreaks of this deadly disease.

Bavarian Nordic's smallpox vaccine, Jynneos, is the only FDA-approved vaccine for the prevention of smallpox in adults. The vaccine has been shown to be safe and effective in clinical trials and has been used in emergency response situations.

Bavarian Nordic expects the contract to have a positive impact on its long-term growth prospects. However, it does not anticipate any material impact on its overall financial guidance for the year.